Lipid-lowering therapy in membranous nephropathy

Kidney International, Supplement

Volumn 56, Issue 71, 1999, Pages

  Haas, Martin ^a   Kerjaschki, Dontscho ^a   Mayer, Gert ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Glomerular injury; Lipid abnormalities; Progressive renal failure; Proteinuria

Indexed keywords

PROBUCOL; ANTILIPEMIC AGENT;

ANIMAL MODEL; CONFERENCE PAPER; GLOMERULUS BASEMENT MEMBRANE; KIDNEY FAILURE; LIPID PEROXIDATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; DRUG EFFECT; HUMAN; MEMBRANOUS GLOMERULONEPHRITIS; METABOLISM; REVIEW;

ANTILIPEMIC AGENTS; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; LIPID PEROXIDATION; PROBUCOL;

EID: 0033014393     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. SCHIEPPATI A, MOSCONI L, PERNA A, MECCA G, BERTANI T, GARATTINI S, REMUZZI G: Prognosis of untreated patients with membranous nephropathy. N Engl J Med 329:85-89, 1993
2. PONTICELLI C, ZUCCHELLI P, PASSERINI P, CESANA B, LOCATELLI F, PASQUALI S, SASDELLI M, RADAELLI B, GRASSI C, POZZI C: A ten year follow up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 48:1600-1604, 1995
3. STEGEMAN CA, DE ZEEUW D, DE JONG PE: Treatment of idiopathic membranous nephropathy: The dilemma of who, when and how. Nephrol Dial Transplant 10:1982-1984, 1995
4. PEI Y, CATTRAN D, GREENWOOD C: Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 42:960-966, 1992
5. JOVEN J, VILLABONA C, VILELLA E, MASANA L, ALBERTI R, VALLES M: Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323:579-584, 1990
6. VEGA GL, TOTE RD, GRUNDY SM: Metabolism of low density lipoproteins in nephrotic dyslipidemia: Comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int 47:579-586, 1995
7. DAVIS RW, STAPRANS I, HUTCHINSON FN, KAYSEN GA: Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 86:600-605, 1990
8. APPEL GB, APPEL AS: Lipid lowering agents in proteinuric diseases. Am J Nephrol 10(Suppl 1):110-115, 1990
9. AUSTIN HA, ANTONOVYCH TT, MACKAY K, BOUMPAS DT, BALOW JE: NIH conference: Membranous nephropathy. Ann Intern Med 116:672-682, 1992
10. KEANE WF: Lipids and the kidney. Kidney Int 46:910-920, 1994
11. MOORHEAD JF, BRUNTON C, FERNANDO RL, BURNS A, VARGHESE Z: Do glomerular atherosclerosis and lipid mediated tubulointerstitial disease cause progressive renal failure in man? Blood Purif 14:58-66, 1996
12. RAYNER BL, BYRNE MJ, VAN ZYL SMIT R: A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin Nephrol 46:219-224, 1996
13. KERJASCHKI D, NEALE TJ: Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol 7:2518-2526, 1996
14. AMBALAVANAN S, FAUVEL JP, SIBLEY RK, MYERS BD: Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J Am Soc Nephrol 7:290-298, 1996
15. FARQUHAR MG, SAITO A, KERJASCHKI D, ORLANDO RA: The Heymann nephritis antigenic complex: Megalin (ep 330) and RAP. J Am Soc Nephrol 6:35-47, 1995
16. SUSANI M, SCHULZE M, EXNER M, KERJASCHKI D: Antibodies to glycolipids activate complement and promote proteinuria in passive Heymann nephritis. Am J Pathol 144:807-819, 1994
17. NEALE TJ, OJHA PP, EXNER M, POCZEWSKI H, RÜGER B, WITZTUM JL, DAVIS P, KERJASCHKI D: Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts of type IV collagen. J Clin Invest 94:1577-1584, 1994
18. KERJASCHKI D, EXNER M, ULLRICH R, SUSANI M, CURTISS LK, WITZTUM JL, FARQUHAR MG, ORLANDO RA: Pathogenetic antibodies inhibit binding of apolipoproteins to megalin/gp330 in passive Heymann nephritis. J Clin Invest 100:2303-2309, 1997
19. EXNER M, SUSANI M, WITZTUM JL, HOVORKA A, CURTISS LK, SPITZAUER S, KERJASCHKI D: Lipoproteins accumulate in immune deposits and are modified by lipid peroxidation in passive Heymann nephritis. Am J Pathol 149:1313-1320, 1996
20. NEALE TJ, ULLRICH R, OJHA P, POCZEWSKI H, VERHOEVEN AJ, KERJASCHKI D: Reactive oxygen species and neutrophil respiratory burst cytochrome b 558 are produced by kidney glomerular cells in passive Heymann nephritis. Proc Natl Acad Sci USA 90:3645-3649, 1993
21. PARTHASARATHY S, YOUNG SG, WITZTUM JL, PITTMAN RC, STEINBERG D: Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 77:641-644, 1986
22. RICARDO SD, BERTRAM JF, RYAN GB: Antioxidants protect podocyte foot processes in puromycin aminonucleoside-treated rats. J Am Soc Nephrol 4:1974-1986, 1994